CORRECTION article

Front. Oncol., 15 January 2025

Sec. Cancer Epidemiology and Prevention

Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1540165

Corrigendum: New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count

  • 1. Data Department, Encore Lab S.L., Logroño, Spain

  • 2. Department of Mechanical Engineering, Universidad de La Rioja, Logroño, Spain

  • 3. Medical Oncology Department, Hospital San Pedro, Logroño, Spain

  • 4. Angiogenesis Group, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain

Article metrics

View details

792

Views

278

Downloads

In the published article, there was an error in Table 4 as published. Error was in the manual transcription of the numerical data of the Kaplan-Meier result. Specifically, the transcription error has occurred for the rows of ALP, GGT and LDH. The corrected Table 4 and its caption “Kaplan-Meier and log-rank values for statistically significant hematologic parameters grouped by the optimal cut-off” appear below.

Table 4

Variablemedian survival (95%CI) (months)
<cut-off point≥cut-off pointNχ2p-value
ALP12.67 (10.17-17.80)7.37 (5.77-10.10)24/728.40.004**
GGT12.30 (8.97-15.30)7.47 (6.07-10.10)31/654.70.031*
LDH12.75 (11.40-14.57)6.42 (4.50-8.93)42/549.80.002**
Leukocytes11.80 (9.50-13.40)6.50 (4.93-9.63)51/457.50.006**
Neutrophiles11.15 (8.97-12.80)6.42 (4.40-9.40)60/365.10.024*
Monocytes11.50 (9.50-12.90)6.40 (5.23-8.93)55/415.80.016*

Kaplan-Meier and log-rank values for statistically significant hematologic parameters grouped by the optimal cut-off.

Asterisks represent statistically significant differences. *: p<0.05; **: p<0.01.

In the published article, there was an error. The error corresponds to the paragraph in which numerical references are made to the Table 4 with the numerical transcription error.

A correction has been made to Results, Prognosis, Paragraph 3. This sentence previously stated:

“Those individuals whose values on GGT and LDH were below the cut-off point (Table 4) presented a better prognosis than the ones who were above; specifically, they presented an OS increase by 44.8%, and 74.6%, respectively (Figures 1B, C). For their part, ALP<102.00 (Figure 1A), number of leukocytes<8,000, neutrophiles<6,000 and monocytes<800 (Figures 1D–F) were also statistically significant, resulting in patients with low levels increasing their survival by 49.7%, 44.9%, 42.5% and 44.4%, respectively (Table 4).”

The corrected sentence appears below:

“Those individuals whose values on GGT and LDH were below the cut-off point (Table 4) presented a better prognosis than the ones who were above; specifically, they presented an OS increase by 39.3%, and 49.6%, respectively (Figures 1B, C). For their part, ALP<102.00 (Figure 1A), number of leukocytes<8,000, neutrophiles<6,000 and monocytes<800 (Figure 1D-F) were also statistically significant, resulting in patients with low levels increasing their survival by 41.8%, 44.9%, 42.4% and 44.3%, respectively (Table 4).”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

prognosis model, prognostic biomarkers, overall survival, gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), advanced and metastatic pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC)

Citation

del Campo-Pedrosa R, Martín-Carnicero A, González-Marcos A and Martínez A (2025) Corrigendum: New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count. Front. Oncol. 14:1540165. doi: 10.3389/fonc.2024.1540165

Received

05 December 2024

Accepted

16 December 2024

Published

15 January 2025

Volume

14 - 2024

Edited and reviewed by

Sharon R. Pine, University of Colorado Anschutz Medical Campus, United States

Updates

Copyright

*Correspondence: Rocío del Campo-Pedrosa,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics